search

European Heart Journal - Quality of Care and Clinical Outcomes, Volume 2, Issue 4, October 2016, Pages 277–284, https://doi.org/10.1093/ehjqcco/qcw013

Published: 26 February 2016

Modify your search

Availability

NARROW

Format

Subject

Type

Collection

Journal

Publication date

Efficacy and safety of inclisiran based on background lipid-lowering treatment

Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial Get access

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1 Get access

The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53 Get access

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey Get access

Modify your search

Publication date

This Feature Is Available To Subscribers Only